Previous 10 | Next 10 |
Image source: The Motley Fool. Ironwood Pharmaceuticals, inc (NASDAQ: IRWD) Q3 2021 Earnings Call Nov 4, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals, inc (IRWD) Q3 2021 Earnings Call Tra...
Ironwood Pharmaceuticals (NASDAQ:IRWD) has entered into a collaboration and license option agreement with COUR Pharmaceutical Development Company, a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. The agreement gives Ironwood an option ...
Ironwood Pharmaceuticals (NASDAQ:IRWD): Q3 Non-GAAP EPS of $0.33 beats by $0.01; GAAP EPS of $0.34 beats by $0.03. Revenue of $103.74M (+0.3% Y/Y) misses by $1.53M. Press Release For further details see: Ironwood Pharmaceuticals EPS beats by $0.01, misses on revenue
– LINZESS ® (Iinaclotide) prescription demand growth increased 12% year-over-year; LINZESS U.S. net sales of $253 million, an increase of 5% year-over-year – – Total revenue of $104 million; U.S. LINZESS collaboration revenue of $100 million...
IND for CNP-104 Accepted by FDA; Clinical Trials Planned for the End of 2021 Ironwood to Make a Payment of approximately $20 Million in Upfront and Near-Term Milestones and up to $475 Million in Long-Term Commercial and Regulatory Milestones and Royalties to COUR I...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is $0.32 (+39.1% Y/Y) and the consensus Revenue Estimate is $105.27M (+1.7% Y/Y). Over the last 2 years, IRWD has beaten EPS estimates ...
Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distr...
- Ironwood to Also Present Data Highlighting Impact of Linaclotide on Abdominal and Bowel-Related Symptoms in Adult Patients with IBS-C - - Separate Surveys Will Highlight Disease Prevalence and Burden Among Patients with GI Conditions - Ironwood Pharmaceuticals, I...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 4, 2021. Individuals interested in participating in the call should dial (888) 330-3181 (U.S....
P/E (5.61), EV/EBITDA (9.28), and Price/Sales (5.37) are 30-80% lower than the sector medians. Balance sheet of IRWD has been steadily improving over the past several years. Revenue has grown since 2016 (CAGR of 21.10%). I don’t believe this low valuation is justified, ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...